The flagship fund of Cathie Wood has recorded its longest run of inflows in more than a year. For eight days in a row, investors have poured money into the $9.5 billion Ark Innovation ETF. The fund is approaching its March 2020 bottom point and has lost 52% so far this year. Cathie Wood anticipated that over the following five years, her Ark Investment Management would yield 40% annually. Cathie Wood’s portfolio includes a number of well-known small-cap firms, such as Pacific Biosciences of California and Schrödinger, Inc.
Insider Monkey highlighted the top 10 small-cap growth stocks in Cathie Wood’s portfolio. A bank holding company called Silvergate Capital Corporation offers solutions and services for the financial infrastructure and has large investments in fintech goods. Cathie Wood’s ARK Investment Management reported holding 478,486 shares worth roughly $72 million in the 13F filings. In the first quarter of 2022, Cathie Wood’s ARK Investment Management boosted its stake in Codexis, Inc. by 22 percent, holding 3.94 million shares worth $81.29 million. Do Kim, a Sandler analyst, anticipates that Molecular Assemblies will finish developing its commercial infrastructure. A firm that finds protein biomarkers and provides clinical diagnostics is called SomaLogic, Inc. Software for computational chemistry is being developed by Schrödinger, Inc., which also has pipeline programs for drug discovery. 2.83 million shares, worth $96.65 million and constituting 0.4 percent of the firm’s portfolio, are held by ARK Investment Management. In the field of immune-driven medicine, Adaptive Biotechnologies Corporation is a pioneer. ARK Investment Management, run by Cathie Wood, owns more than 7.7 million shares in the business. The second test offered by the firm is T-Detect Lyme. For more details, click 10 Small-Cap Growth Stocks In Cathie Wood’s Portfolio.
